is the fda stopping compounded tirzepatide moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified Compounded Semaglutide & Tirzepatide 2025:

Metoclopramide carries an FDA black box warning for tardive dyskinesia with use exceeding 12 weeks and should only be used under careful medical supervision with appropriate monitoring

Effective 1 Complete Online Assessment Tell us about your health and weight loss goals

Community reports suggest the combination produces approximately 60% better outcomes than either peptide alone for significant injuries

Long-term data from the SELECT trial published in 2023 showed reduced major adverse cardiovascular events among adults with obesity and existing cardiovascular disease, making semaglutide a medication with implications beyond weight alone

In this article, we explore the scientific evidence, the types of hair loss reported during treatment, and the biological mechanisms that might explain the connection, separating what research supports from what remains uncertain

But as its popularity surges, so does the controversy surrounding it